SecBot SecBot
SECBOTREPLAY Home › Report › ABUS

ABUS · Arbutus Biopharma announced plans to launch a modified Dutch auction…

Arbutus Biopharma Corp · 8-K filed Aug 21, 2026 at 07:53 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 21, 2026 at 07:53 ET

Arbutus Biopharma announced plans to launch a modified Dutch auction tender offer to repurchase up to $230 million of its common shares at $5.00–$5.75 per share, funded by cash on hand from its March 2026 settlement with Moderna. The offer is contingent on receiving exemptive relief from Canadian and U.S. securities regulators and has not yet commenced. This is a significant capital return event for a clinical-stage biotech, signaling management's confidence in its cash position and IP enforcement strategy, but the offer is not yet binding and faces regulatory hurdles.

  • Arbutus plans to repurchase up to $230 million of its common shares via a modified Dutch auction tender offer.
  • The purchase price range is $5.00 to $5.75 per share.
  • The offer is expected to commence on or about August 24, 2026, and expire on or about September 29, 2026.
  • Funding will come from cash on hand, referencing the March 2026 settlement with Moderna and a July 2026 initial payment.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access